Endothelial-Targeted Metallothionein-2 shRNA Nanoparticles Alleviate Migraine-Like Symptoms

Area of Science:

• Neuroscience
• Vascular Biology
• Molecular Medicine

Background:

• Migraine is a prevalent neurological disorder with variable treatment responses.
• Metallothionein-2 (Mt2) has an unexplored role in migraine pathophysiology.

Purpose of the Study:

• To investigate the function of metallothionein-2 (Mt2) in migraine.
• To explore Mt2's role in vascular endothelial cells during migraine.

Main Methods:

• Utilized EGR1-GFP reporter system and RNA sequencing to identify Mt2 upregulation in activated cortical cells after nitroglycerin (NTG) induction.
• Engineered endothelial-targeted nanoparticles with Mt2-shRNA for administration in migraine model mice.
• Assessed migraine behaviors (photophobia, hyperalgesia) and cerebral vasodilation via two-photon microscopy.

Main Results:

• Downregulation of Mt2 in endothelial cells significantly reduced migraine-related behaviors and attenuated NTG-induced cerebral vasodilation.
• RNA sequencing and pathway analysis indicated Mt2's involvement in cerebrovascular endothelial cell development, migration, and inflammation.
• Mt2 was identified as a key regulator of vascular tone and inflammatory signaling in migraine.

Conclusions:

• Metallothionein-2 (Mt2) is implicated in migraine pathogenesis through its regulation of vascular tone and inflammation.
• Targeting Mt2 in endothelial cells presents a potential therapeutic strategy for migraine.
• Findings offer insights into the vascular mechanisms underlying migraine.